The Interaction Between Neuroinflammation and β-Amyloid in Cognitive Decline in Parkinson’s Disease

被引:0
|
作者
Christine Ghadery
Yuko Koshimori
Leigh Christopher
Jinhee Kim
Pablo Rusjan
Anthony E. Lang
Sylvain Houle
Antonio P. Strafella
机构
[1] University of Toronto,Research Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health
[2] University of Toronto,Krembil Research Institute, University Health Network (UHN)
[3] University of Toronto,E.J. Safra Parkinson Disease Program & Morton and Gloria Shulman Movement Disorder Unit, Neurology Division, Department of Medicine, Toronto Western Hospital, UHN
来源
Molecular Neurobiology | 2020年 / 57卷
关键词
Neuroinflammation; β-Amyloid; PET imaging; Parkinson’s disease; Cognitive impairment;
D O I
暂无
中图分类号
学科分类号
摘要
Activated microglia have been reported to play an important role in Parkinson’s disease (PD). A more rapid cognitive decline has been associated with deposits of β-amyloid. In this study, the aim was to evaluate the role of brain β-amyloid and its relationship with activated microglia in PD patients with normal and impaired cognition. We studied 17 PD patients with normal cognition (PDn), 12 PD patients with mild cognitive impairment (PD-MCI), and 12 healthy controls (HCs) with [11C] Pittsburgh compound B (PIB) to assess the impact of β-amyloid deposition in the brain on microglial activation evaluated using the translocator protein 18-kDa (TSPO) radioligand [18F]-FEPPA. [11C] PIB distribution volume ratio was measured in cortical and subcortical regions. [18F]-FEPPA total distribution volume values were compared for each brain region between groups to evaluate the effect of PIB positivity while adjusting for the TSPO rs6971 polymorphism. Factorial analysis of variance revealed a significant main effect of PIB positivity in the frontal lobe (F(1, 34) = 7.1, p = 0.012). Besides the frontal (p = 0.006) and temporal lobe (p = 0.001), the striatum (p = 0.018), the precuneus (p = 0.019), and the dorsolateral prefrontal cortex (p = 0.010) showed significant group × PIB positivity interaction effects. In these regions, PD-MCIs had significantly higher FEPPA VT if PIB-positive. Our results indicate an interaction between amyloid-β deposition and microglial activation in PD. Further investigations are necessary to evaluate if amyloid deposits cause neuroinflammation and further neurodegeneration or if increased microglia activation develops as a protective response.
引用
收藏
页码:492 / 501
页数:9
相关论文
共 50 条
  • [21] Genetic influences on cognitive decline in Parkinson's disease
    Morley, James F.
    Xie, Sharon X.
    Hurtig, Howard I.
    Stern, Matthew B.
    Colcher, Amy
    Horn, Stacy
    Dahodwala, Nabila
    Duda, John E.
    Weintraub, Daniel
    Chen-Plotkin, Alice S.
    Van Deerlin, Vivianna
    Falcone, Dana
    Siderowf, Andrew
    MOVEMENT DISORDERS, 2012, 27 (04) : 512 - 518
  • [22] Sleep as a predictor of cognitive decline in Parkinson's disease
    Kawada, Tomoyuki
    SLEEP MEDICINE, 2021, 85 : 324 - 324
  • [23] Cognitive decline in Parkinson’s disease: the complex picture
    Biundo R.
    Weis L.
    Antonini A.
    npj Parkinson's Disease, 2 (1)
  • [24] Cognitive decline before diagnosis of Parkinson's disease
    Darweesh, Sirwan K. L.
    Koudstaal, Peter J.
    Ikram, M. Kamran
    Ikram, M. Arfan
    LANCET NEUROLOGY, 2017, 16 (04): : 262 - 262
  • [25] Trajectories of cognitive and functional decline in Parkinson's disease
    Goldman, Jennifer
    Merkitch, Douglas
    Bernard, Bryan
    Negron, Alice
    Stebbins, Glenn
    NEUROLOGY, 2019, 92 (15)
  • [26] Genetic influences on cognitive decline in Parkinson's disease
    Morley, J. F.
    Xie, S. X.
    Hurtig, H. I.
    Stern, M. B.
    Colcher, A.
    Horn, S.
    Dahodwala, N.
    Duda, J. E.
    Weintraub, D.
    Chen-Plotkin, A. S.
    Van Deerlin, V.
    Falcone, D.
    Siderowf, A.
    MOVEMENT DISORDERS, 2012, 27 : S32 - S33
  • [27] Serial DTI and cognitive decline in Parkinson's disease
    Melzer, T. R.
    Watts, R.
    MacAskill, M. R.
    Pitcher, T. L.
    Livingston, L.
    Keenan, R.
    Dalrymple-Alford, J. C.
    Anderson, T. J.
    MOVEMENT DISORDERS, 2013, 28 : S196 - S197
  • [28] Biomarkers for cognitive decline of early Parkinson's disease
    Bereczki, E.
    Francis, P.
    Ballard, C.
    Hoglund, K.
    Svenningsson, P.
    Aarsland, D.
    MOVEMENT DISORDERS, 2014, 29 : S338 - S338
  • [29] Motor subtype and cognitive decline in Parkinson's disease
    Tran, B.
    Rick, J.
    Pigott, K.
    Chen-Plotkin, A.
    Hurtig, H.
    Dahod-Wala, N.
    Chahine, L.
    Akhtar, R.
    Duda, J.
    Morley, J.
    Fleisher, J.
    Siderowf, A.
    Xie, S.
    Trojanowski, J.
    Weintraub, D.
    MOVEMENT DISORDERS, 2014, 29 : S368 - S369
  • [30] Anticholinergic activity and cognitive decline in Parkinson's disease
    Starkstein, Sergio E.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 (02): : 129 - 129